/C O R R E C T I O N — ChromaDex Corporation/
In the news release, ChromaDex® Announces Expanded Retail Distribution for its BluScience(TM) Line of Dietary Supplements at a National Drug Store Chain, issued
ChromaDex® Announces Expanded Retail Distribution for its BluScience(TM) Line of Dietary Supplements at a National Drug Store Chain
BluScience expected to be available in 25,000+ retail stores by year-end 2012
IRVINE, Calif., Jan. 10, 2012 /PRNewswire/ — ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries announced today that its BluScience line of dietary supplements is now available for sale in one of the largest retail drug store chains with more than 8,000 stores throughout the United States.
This national chain will be carrying two BluScience SKUs (HeartBlu and EternalBlu) by the end of Q1 2012 and two additional SKUs (MemoryBlu and Blu2Go) by the end of Q2 2012. This marks the first rollout of BluScience into retail mass merchants since the initial launch of the product at GNC.
The novel ingredient in BluScience is ChromaDex’s proprietary, patent-pending pterostilbene, branded as pTeroPure®, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan.
pTeroPure is a proprietary, nature-identical formulation of the antioxidant compound pterostilbene, which is found naturally in blueberries. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols, allowing more time for its antioxidant activities to act. Along with a number of other effects, pterostilbene has shown great promise for supporting cardiovascular health, cognitive function and anti-aging. However, the amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits. In fact, one BluScience capsule has the equivalent amount of pterostilbene as contained in more than 500 cartons of blueberries.
Commenting on the announcement, Ann Deren-Lewis, Vice President of Marketing of ChromaDex, stated, “This additional retail distribution will complement the existing availability of BluScience at GNC. Given the favorable response we are hearing from mass merchant retailers, our goal is to have BluScience available at more than 25,000 retail outlets by the end of 2012. The Q1 national rollout of the product is being matched by a comprehensive television, print and online advertising strategy with a focus on developing education and awareness around the benefits of both pTeroPure and our BluScience line of retail products.”
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure®( )pterostilbene for which it has worldwide, exclusive patent pending rights. The Company recently launched its BluScience(TM) line of dietary supplements. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure( )for the skincare and pharmaceutical markets, among others. pTeroPure( )is currently being studied in a human clinical trial at the University of Mississippi.
For more information about pTeroPure( )visit www.pteropure.com or call 949-600-9694.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
Liviakis Financial Communications, Inc.
John M. Liviakis, President
Institutions and Analysts Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
SOURCE ChromaDex Corporation